581073-80-5

Basic information

• Product Name: KJ Pyr 9
• Synonyms: KJ Pyr 9
• CAS NO: 581073-80-5
• Molecular Formula: C22H15N3O4
• Molecular Weight: 385.3722
• Mol File: 581073-80-5.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 584.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.320±0.06 g/cm3(Predicted)
• Solubility: ≤20mg/ml in DMSO;25mg/ml in dimethyl formamide
• PKA: 15.34±0.50(Predicted)
• CAS DataBase Reference: KJ Pyr 9(CAS DataBase Reference)
• NIST Chemistry Reference: KJ Pyr 9(581073-80-5)
• EPA Substance Registry System: KJ Pyr 9(581073-80-5)

Safety Data

• Hazardous Substances Data: 581073-80-5(Hazardous Substances Data)

Usage

Description

KJ Pyr 9, also known as 4-[2-(2-Furanyl)-6-(4-nitrophenyl)-4-pyridinyl]benzamide, is a chemical compound with potent anti-cancer properties. It has been found to inhibit MYC-induced oncogenic transformation in cell culture and effectively block the growth of a xenotransplant of MYC-amplified human cancer cells. Its unique structure and mechanism of action make it a promising candidate for further research and development in the field of oncology.

Uses

Used in Pharmaceutical Industry:
KJ Pyr 9 is used as an anti-cancer agent for its ability to inhibit MYC-induced oncogenic transformation in cell culture. This makes it a potential therapeutic option for treating various types of cancer, particularly those with MYC amplification.
Used in Cancer Research:
KJ Pyr 9 is used as a research tool for studying the role of MYC in cancer development and progression. Its ability to block the growth of MYC-amplified cancer cells can provide valuable insights into the underlying molecular mechanisms and help identify potential targets for novel cancer therapies.
Used in Drug Development:
KJ Pyr 9 serves as a lead compound in the development of new anti-cancer drugs. Its potent inhibitory effects on MYC-induced oncogenic transformation make it a valuable starting point for designing and synthesizing more effective and targeted cancer treatments.
Used in Drug Delivery Systems:
Similar to gallotannin, KJ Pyr 9 can also benefit from novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles can be employed as carriers for KJ Pyr 9 delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes.

Biological Activity

mkj pyr 9 is a novel small molecule inhibitor of myc, with the kd value of 6.5 ± 1.0 nm. besides, kj pyr 9 also suppresses the formation of myc-max and oncogenic transformation induced by myc in cell culture [1].

in vitro

in chicken embryo fibroblasts, kj pyr 9 was found to have the ability to interfere with the oncogenic activity of myc, with the best aqueous solubility. besides, in human b-cell line p493-6, 20 μm kj pyr 9 could significantly inhibit cell proliferation, and kj pyr 9 could also inhibit the proliferation of nci-h460, mda-mb-231, and sum-159pt cell lines, with the ic50 values between 5-10 μm. furthermore, treatment of p493-6 cells with kj pyr 9 could significantly suppress the transcription ability of myc [1].

in vivo

kj pyr 9 was found to have no acute toxicity in mouse and rat at a dose of 10 mg/kg, with an impressive ability to cross the blood-brain barrier. besides, in a mda-mb-231 cells xenograft tumor nude mice model, intraperitoneal injection with 10 mg/kg kj pyr 9 for 31 days could significantly inhibit tumor growth, while having no effect on the body weight [1].

target

myc

references

[1] hart j r, garner a l, yu j, et al. inhibitor of myc identified in a kr?hnke pyridine library[j]. proceedings of the national academy of sciences, 2014, 111(34): 12556-12561.